Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies


March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building is weathertight, a major milestone with significance for Shine, the medical isotope industry and patients around the world.

Reaching the weathertight milestone moves Shine one step closer to providing a flexible, reliable supply of molybdenum-99 (Mo-99) and other neutron-produced isotopes to customers, physicians and patients. It means that the 46,000-square-foot building is now sealed against the elements and the installation of Shine’s high-tech process equipment can begin. The production facility has been built to withstand tornados, airplane crashes and other catastrophic events, and is expected to be a major producer of medicine for decades to come.

“This milestone marks a leveling-up for our team, which includes our internal staff, but also all those who helped do the work in the field,” said Greg Piefer, founder and CEO of Shine. “We’ve now demonstrated we can execute against a challenging first-of-a-kind nuclear build and do so within schedule and budget contingencies— all during a global pandemic. I am incredibly proud of the grit, dedication and skill of all those involved as we worked together to tackle complicated problems in challenging conditions. The results of the team’s hard work say a lot about their extraordinary dedication, talent and commitment to improving the lives of patients everywhere.”

The plant is expected to be the largest medical isotope production facility in the world by capacity. Shine is installing the specialized process equipment in the facility during the next year, and expects to begin producing Mo-99 in late 2022.

“Baker Concrete Construction is proud to be one of Shine’s partner in the construction of this important facility and we’re excited to have been given the opportunity to play a key role in getting the project to weathertight,” said Matt Jorn, project executive of Baker. “We understand what this plant means, not just to Shine, but to patients around the globe. This commitment makes our involvement in the facility’s construction even more meaningful. Doing our part to bring the facility to weathertight is something that the entire Baker team takes great pride in.”

In addition to Baker, Shine’s construction partners include J.H. Findorff & Son Inc., Sargent & Lundy LLC, Lycon Inc., and Westphal & Co.

For more information: www.shinemed.com

Related Shine Isotope Production News:

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes

Shine Medical Approved to Build Domestic Molybdenum-99 Production Facility

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

World Record for Strongest Nuclear Fusion Reaction in a Steady-State System Achieved by Phoenix and Shine

Related Content

News | Prostate Cancer

January 24, 2022 — New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk ...

Time January 24, 2022
arrow
News | Prostate Cancer

January 19, 2022 — For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used ...

Time January 19, 2022
arrow
News | Lung Imaging

January 17, 2022 — A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung ...

Time January 17, 2022
arrow
News | Radiation Therapy

January 13, 2022 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance ...

Time January 13, 2022
arrow
News | Molecular Imaging

Janaury 10, 2022 — The Department of Energy’s National Nuclear Security Administration (NNSA) and Office of ...

Time January 10, 2022
arrow
News | Radiation Oncology

January 7, 2022 — Varian and parent company Siemens Healthineers have been recognized in the annual IMV ServiceTrak ...

Time January 07, 2022
arrow
News | Radiation Oncology

January 7, 2022 — A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to ...

Time January 07, 2022
arrow
News | Proton Therapy

January 3, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and ...

Time January 03, 2022
arrow
News | Computed Tomography (CT)

January 3, 2022 — The "Computed Tomography (CT) Scanners Devices and Equipment Global Market Report 2021: COVID-19 ...

Time January 03, 2022
arrow
News | Radiation Oncology

December 30, 2021 — IBA (Ion Beam Applications S.A), a world leader in particle accelerator technology, announced the ...

Time December 30, 2021
arrow
Subscribe Now